U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07618377) titled 'Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments' on May 25.
Brief Summary: To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Gastrointestinal Stromal Tumors
Intervention:
DRUG: DCC-2618
DCC-2618 150 mg, administered orally once daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ono Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....